{
    "info": {
        "nct_id": "NCT03346135",
        "official_title": "A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma",
        "inclusion_criteria": "* All subjects must have the ability to understand and the willingness to sign a written informed consent\n* Histologically confirmed diagnosis of multiple myeloma; (patients with multiple myeloma with secondary amyloidosis are eligible)\n* Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-13 months of the first dose of initial therapy\n* Eastern Cooperative Oncology Group (ECOG) =< 2\n* Patients with planned standard of care ASCT using melphalan 200 mg/m^2; dose modifications in accordance with creatinine clearance levels are allowed per physician judgment\n* Adequate organ function for high dose chemotherapy and autologous stem cell transplant (as per institution standard operating procedure [SOP])\n* Adequate cell dose > 2.5 x 10^6 CD34+ cells/kg\n* Absolute neutrophil count (ANC) >= 1000/mm^3\n* Platelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollment\n* Total bilirubin =< 1.5 x the upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) =< 3 x ULN\n* Alanine aminotransferase (ALT) =< 3 x ULN\n* Calculated creatinine clearance >= 30 mL/min\n* Woman of childbearing potential must be practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: e.g., established use of oral, injected, or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods; condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization; true abstinence (when this is in line with the preferred and usual lifestyle of the subject) during and after the study (6 months after the last dose of daratumumab for women)\n\n  * A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 6 months after receiving the last dose of study drug\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
        "exclusion_criteria": "* Prior disease progression with daratumumab or other anti-CD38 antibody\n* History of organ or previous autologous/allogeneic stem cell transplantation\n* Any condition medical or psychosocial that in the opinion of the investigator would hinder compliance\n* Female patients who are lactating or have a positive pregnancy test during the screening period\n* Evidence of multiple myeloma (MM) disease progression any time prior to enrollment; progression from smoldering to active myeloma is not exclusionary\n* History of plasma cell leukemia or central nervous system (CNS) involvement\n* Major surgery within 14 days prior to start of study treatment\n* Infection requiring systemic antibiotic therapy within 14 days prior to the start of study treatment\n* Subject is receiving concurrent chemotherapy or biologic or hormonal therapy for cancer treatment; Note: Concurrent use of hormones for noncancer-related conditions (e.g., insulin for diabetes) is acceptable\n* Vaccination with live attenuated vaccines within 4 weeks of first study agent administration\n* Subject is currently using or has used immunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions:\n\n  * Intranasal, topical, inhaled, or local steroid injections (e.g., intra-articular injection)\n  * Chronic systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent\n  * Steroids as premedication for hypersensitivity reaction (e.g., infusion-related reactions, computed tomography [CT] scan premedication)\n* Subject has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloidosis\n* Subjects with uncontrolled, systematic infection should be excluded\n* Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% predicted normal; Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50%\n* Subject has known moderate or severe persistent asthma within 2 years, or currently has uncontrolled asthma of any classification; (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study)\n* Subject has active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., Crohn's disease], diverticulitis, celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener syndrome; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis, etc) within the past 3 years prior to the start of treatment; the following are exceptions:\n\n  * Subjects with vitiligo or alopecia\n  * Subjects with hypothyroidism (e.g., following Hashimoto's disease) stable on hormone replacement\n  * Psoriasis not requiring systemic treatment\n* Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients\n* Subject has history of primary immunodeficiency\n* Subject is seropositive for human immunodeficiency virus (HIV-1)\n* Active hepatitis A\n* Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]); subjects with resolved infection (I.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs] must be screened using real-time polymerase chain reaction [PCR] measurement of hepatitis B virus [HBV] deoxyribonucleic acid [DNA] levels; those who are PCR positive will be excluded); EXCEPTION: Subjects with serologic finding suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR\n* Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)\n* Subject has any one of the following:\n\n  * Clinically significant abnormal electrocardiogram (ECG) finding at screening\n  * Congestive heart failure (New York Heart Association class III or IV)\n  * Myocardial infarction within 12 months prior to starting study treatment\n  * Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris\n* Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease for >= 5 years with the exception of the following malignancies:\n\n  * Basal cell carcinoma of the skin\n  * Squamous cell carcinoma of the skin\n  * Carcinoma in situ of the cervix\n  * Carcinoma in situ of the breast\n  * Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system) or prostate cancer that is curative\n* Any other condition that would, in the opinion of the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patients with planned standard of care ASCT using melphalan 200 mg/m^2; dose modifications in accordance with creatinine clearance levels are allowed per physician judgment",
            "criterions": [
                {
                    "exact_snippets": "planned standard of care ASCT",
                    "criterion": "autologous stem cell transplant (ASCT)",
                    "requirements": [
                        {
                            "requirement_type": "planned treatment",
                            "expected_value": "standard of care ASCT"
                        }
                    ]
                },
                {
                    "exact_snippets": "using melphalan 200 mg/m^2",
                    "criterion": "melphalan dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "=",
                                "value": 200,
                                "unit": "mg/m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "dose modifications in accordance with creatinine clearance levels are allowed per physician judgment",
                    "criterion": "melphalan dose modification based on creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "dose modification allowance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "basis for modification",
                            "expected_value": "creatinine clearance levels"
                        },
                        {
                            "requirement_type": "physician judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) =< 3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) =< 3 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-13 months of the first dose of initial therapy",
            "criterions": [
                {
                    "exact_snippets": "Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma",
                    "criterion": "initial systemic therapy cycles for multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cycles"
                            }
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": "systemic"
                        },
                        {
                            "requirement_type": "therapy indication",
                            "expected_value": "multiple myeloma"
                        }
                    ]
                },
                {
                    "exact_snippets": "are within 2-13 months of the first dose of initial therapy",
                    "criterion": "time since first dose of initial therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since first dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 13,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x the upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x the upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All subjects must have the ability to understand and the willingness to sign a written informed consent",
            "criterions": [
                {
                    "exact_snippets": "ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function for high dose chemotherapy and autologous stem cell transplant (as per institution standard operating procedure [SOP])",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function for high dose chemotherapy and autologous stem cell transplant (as per institution standard operating procedure [SOP])",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": "adequate for high dose chemotherapy and autologous stem cell transplant as per institution SOP"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 75,000/mm^3; platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 75,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet transfusions to help patients meet eligibility criteria are not allowed within 7 days before study enrollment",
                    "criterion": "platelet transfusions within 7 days before study enrollment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Woman of childbearing potential must be practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: e.g., established use of oral, injected, or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods; condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization; true abstinence (when this is in line with the preferred and usual lifestyle of the subject) during and after the study (6 months after the last dose of daratumumab for women)",
            "criterions": [
                {
                    "exact_snippets": "Woman of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be practicing a highly effective method of birth control ... during and after the study (6 months after the last dose of daratumumab for women)",
                    "criterion": "birth control method",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during and 6 months after the last dose of daratumumab"
                        }
                    ]
                },
                {
                    "exact_snippets": "consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies",
                    "criterion": "compliance with local regulations for birth control",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1000/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed diagnosis of multiple myeloma; (patients with multiple myeloma with secondary amyloidosis are eligible)",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed diagnosis of multiple myeloma",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with multiple myeloma with secondary amyloidosis are eligible",
                    "criterion": "secondary amyloidosis in multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) =< 3 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 3 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 6 months after receiving the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "A man who is sexually active with a woman of childbearing potential",
                    "criterion": "sexual activity with a woman of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has not had a vasectomy",
                    "criterion": "vasectomy status",
                    "requirements": [
                        {
                            "requirement_type": "history of vasectomy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use a barrier method of birth control, e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository",
                    "criterion": "use of barrier method of birth control",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "all men must also not donate sperm during the study and for 6 months after receiving the last dose of study drug",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "prohibition period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "during the study"
                                    },
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "for 6 months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate cell dose > 2.5 x 10^6 CD34+ cells/kg",
            "criterions": [
                {
                    "exact_snippets": "Adequate cell dose > 2.5 x 10^6 CD34+ cells/kg",
                    "criterion": "CD34+ cell dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2500000.0,
                                "unit": "CD34+ cells/kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calculated creatinine clearance >= 30 mL/min",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance >= 30 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 70 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 70 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 70,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Basal cell carcinoma of the skin",
            "criterions": [
                {
                    "exact_snippets": "Basal cell carcinoma of the skin",
                    "criterion": "basal cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vaccination with live attenuated vaccines within 4 weeks of first study agent administration",
            "criterions": [
                {
                    "exact_snippets": "Vaccination with live attenuated vaccines within 4 weeks of first study agent administration",
                    "criterion": "vaccination with live attenuated vaccines",
                    "requirements": [
                        {
                            "requirement_type": "time since vaccination",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant abnormal electrocardiogram (ECG) finding at screening",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant abnormal electrocardiogram (ECG) finding at screening",
                    "criterion": "electrocardiogram (ECG) finding",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of multiple myeloma (MM) disease progression any time prior to enrollment; progression from smoldering to active myeloma is not exclusionary",
            "criterions": [
                {
                    "exact_snippets": "Evidence of multiple myeloma (MM) disease progression any time prior to enrollment",
                    "criterion": "multiple myeloma disease progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "any time prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "progression from smoldering to active myeloma is not exclusionary",
                    "criterion": "progression from smoldering to active myeloma",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition medical or psychosocial that in the opinion of the investigator would hinder compliance",
            "criterions": [
                {
                    "exact_snippets": "Any condition medical or psychosocial that in the opinion of the investigator would hinder compliance",
                    "criterion": "medical or psychosocial condition",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion of hindrance to compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has history of primary immunodeficiency",
            "criterions": [
                {
                    "exact_snippets": "history of primary immunodeficiency",
                    "criterion": "primary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of organ or previous autologous/allogeneic stem cell transplantation",
            "criterions": [
                {
                    "exact_snippets": "History of organ ... transplantation",
                    "criterion": "organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... previous autologous/allogeneic stem cell transplantation",
                    "criterion": "autologous stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... previous autologous/allogeneic stem cell transplantation",
                    "criterion": "allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator's opinion on compliance",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": "satisfactory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject is seropositive for human immunodeficiency virus (HIV-1)",
            "criterions": [
                {
                    "exact_snippets": "seropositive for human immunodeficiency virus (HIV-1)",
                    "criterion": "HIV-1 infection",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psoriasis not requiring systemic treatment",
            "criterions": [
                {
                    "exact_snippets": "Psoriasis not requiring systemic treatment",
                    "criterion": "psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "systemic treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with uncontrolled, systematic infection should be excluded",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled, systematic infection should be excluded",
                    "criterion": "systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other condition that would, in the opinion of the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
            "criterions": [
                {
                    "exact_snippets": "Any other condition that would, in the opinion of the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
                    "criterion": "any other condition contraindicating participation due to safety concerns",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety concern with clinical study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Steroids as premedication for hypersensitivity reaction (e.g., infusion-related reactions, computed tomography [CT] scan premedication)",
            "criterions": [
                {
                    "exact_snippets": "Steroids as premedication for hypersensitivity reaction (e.g., infusion-related reactions, computed tomography [CT] scan premedication)",
                    "criterion": "steroid premedication",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": [
                                "hypersensitivity reaction",
                                "infusion-related reactions",
                                "computed tomography (CT) scan premedication"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of plasma cell leukemia or central nervous system (CNS) involvement",
            "criterions": [
                {
                    "exact_snippets": "History of plasma cell leukemia",
                    "criterion": "plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "central nervous system (CNS) involvement",
                    "criterion": "central nervous system (CNS) involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has any one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Subject has any one of the following:",
                    "criterion": "presence of at least one of a list of conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject is currently using or has used immunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Subject is currently using or has used immunosuppressive medication within 14 days prior to the first dose of study treatment",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use within 14 days prior to first dose",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 14 days prior to start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 14 days prior to start of study treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "event occurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% predicted normal; Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50%",
            "criterions": [
                {
                    "exact_snippets": "known chronic obstructive pulmonary disease (COPD)",
                    "criterion": "chronic obstructive pulmonary disease (COPD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "forced expiratory volume in 1 second (FEV1) < 50% predicted normal ... FEV1 < 50%",
                    "criterion": "forced expiratory volume in 1 second (FEV1)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "% predicted normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Squamous cell carcinoma of the skin",
            "criterions": [
                {
                    "exact_snippets": "Squamous cell carcinoma of the skin",
                    "criterion": "squamous cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject is receiving concurrent chemotherapy or biologic or hormonal therapy for cancer treatment; Note: Concurrent use of hormones for noncancer-related conditions (e.g., insulin for diabetes) is acceptable",
            "criterions": [
                {
                    "exact_snippets": "Subject is receiving concurrent chemotherapy or biologic or hormonal therapy for cancer treatment",
                    "criterion": "concurrent cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "chemotherapy",
                                "biologic",
                                "hormonal"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Carcinoma in situ of the cervix",
            "criterions": [
                {
                    "exact_snippets": "Carcinoma in situ of the cervix",
                    "criterion": "carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure (New York Heart Association class III or IV)",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure (New York Heart Association class III or IV)",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "New York Heart Association class III",
                                "New York Heart Association class IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chronic systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent",
            "criterions": [
                {
                    "exact_snippets": "Chronic systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent",
                    "criterion": "chronic systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day of prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "use_type",
                            "expected_value": "physiologic doses"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active hepatitis A",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis A",
                    "criterion": "hepatitis A",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Carcinoma in situ of the breast",
            "criterions": [
                {
                    "exact_snippets": "Carcinoma in situ of the breast",
                    "criterion": "carcinoma in situ of the breast",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intranasal, topical, inhaled, or local steroid injections (e.g., intra-articular injection)",
            "criterions": [
                {
                    "exact_snippets": "Intranasal, topical, inhaled, or local steroid injections",
                    "criterion": "steroid administration route",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "intranasal",
                                "topical",
                                "inhaled",
                                "local injection"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients who are lactating or have a positive pregnancy test during the screening period",
            "criterions": [
                {
                    "exact_snippets": "Female patients who are lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have a positive pregnancy test during the screening period",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the screening period"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has known moderate or severe persistent asthma within 2 years, or currently has uncontrolled asthma of any classification; (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study)",
            "criterions": [
                {
                    "exact_snippets": "known moderate or severe persistent asthma within 2 years",
                    "criterion": "persistent asthma (moderate or severe)",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "currently has uncontrolled asthma of any classification",
                    "criterion": "asthma control status",
                    "requirements": [
                        {
                            "requirement_type": "current_control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]); subjects with resolved infection (I.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs] must be screened using real-time polymerase chain reaction [PCR] measurement of hepatitis B virus [HBV] deoxyribonucleic acid [DNA] levels; those who are PCR positive will be excluded); EXCEPTION: Subjects with serologic finding suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
            "criterions": [
                {
                    "exact_snippets": "Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg])",
                    "criterion": "hepatitis B serostatus",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HBsAg test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs] must be screened using real-time polymerase chain reaction [PCR] measurement of hepatitis B virus [HBV] deoxyribonucleic acid [DNA] levels; those who are PCR positive will be excluded",
                    "criterion": "hepatitis B virus DNA (HBV DNA) by PCR",
                    "requirements": [
                        {
                            "requirement_type": "screening indication",
                            "expected_value": "required if HBsAg negative and anti-HBc and/or anti-HBs positive"
                        },
                        {
                            "requirement_type": "PCR result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with serologic finding suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR",
                    "criterion": "HBV vaccination status and serology",
                    "requirements": [
                        {
                            "requirement_type": "anti-HBs positivity as only marker",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history of prior HBV vaccination",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requirement for HBV DNA PCR testing",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)",
            "criterions": [
                {
                    "exact_snippets": "Seropositive for hepatitis C",
                    "criterion": "hepatitis C serostatus",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy",
                    "criterion": "sustained virologic response (SVR) to hepatitis C therapy",
                    "requirements": [
                        {
                            "requirement_type": "SVR status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "aviremia duration after therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., Crohn's disease], diverticulitis, celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener syndrome; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis, etc) within the past 3 years prior to the start of treatment; the following are exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Subject has active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., Crohn's disease], diverticulitis, celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener syndrome; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis, etc) within the past 3 years prior to the start of treatment",
                    "criterion": "autoimmune or inflammatory disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "prior documented"
                            ]
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease for >= 5 years with the exception of the following malignancies:",
            "criterions": [
                {
                    "exact_snippets": "prior history of malignancies, other than MM, unless the subject has been free of the disease for >= 5 years with the exception of the following malignancies",
                    "criterion": "prior history of malignancies (other than MM)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "MM"
                            }
                        },
                        {
                            "requirement_type": "disease-free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system) or prostate cancer that is curative",
            "criterions": [
                {
                    "exact_snippets": "Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system)",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "T1a",
                                "T1b"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "prostate cancer that is curative",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "curative",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with vitiligo or alopecia",
            "criterions": [
                {
                    "exact_snippets": "Subjects with vitiligo",
                    "criterion": "vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with ... alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction within 12 months prior to starting study treatment",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction within 12 months prior to starting study treatment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_time_before_study",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Infection requiring systemic antibiotic therapy within 14 days prior to the start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Infection requiring systemic antibiotic therapy within 14 days prior to the start of study treatment",
                    "criterion": "infection requiring systemic antibiotic therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to the start of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior disease progression with daratumumab or other anti-CD38 antibody",
            "criterions": [
                {
                    "exact_snippets": "Prior disease progression with daratumumab or other anti-CD38 antibody",
                    "criterion": "disease progression with daratumumab or other anti-CD38 antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris",
            "criterions": [
                {
                    "exact_snippets": "Unstable or poorly controlled angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prinzmetal variant angina pectoris",
                    "criterion": "Prinzmetal variant angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with hypothyroidism (e.g., following Hashimoto's disease) stable on hormone replacement",
            "criterions": [
                {
                    "exact_snippets": "Subjects with hypothyroidism",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable on hormone replacement",
                    "criterion": "hormone replacement therapy for hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloidosis",
            "criterions": [
                {
                    "exact_snippets": "plasma cell leukemia",
                    "criterion": "plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Waldenstrom's macroglobulinemia",
                    "criterion": "Waldenstrom's macroglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)",
                    "criterion": "POEMS syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "primary amyloidosis",
                    "criterion": "primary amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients",
            "criterions": [
                {
                    "exact_snippets": "known allergies ... to monoclonal antibodies",
                    "criterion": "allergy to monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known allergies ... to human proteins",
                    "criterion": "allergy to human proteins",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known allergies ... to their excipients",
                    "criterion": "allergy to excipients of monoclonal antibodies or human proteins",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity ... to monoclonal antibodies",
                    "criterion": "hypersensitivity to monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity ... to human proteins",
                    "criterion": "hypersensitivity to human proteins",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity ... to their excipients",
                    "criterion": "hypersensitivity to excipients of monoclonal antibodies or human proteins",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerance to monoclonal antibodies",
                    "criterion": "intolerance to monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerance to human proteins",
                    "criterion": "intolerance to human proteins",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerance to ... their excipients",
                    "criterion": "intolerance to excipients of monoclonal antibodies or human proteins",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}